Abbvie (ABBV) Allergan Deal on Track, Mizuho Securities Reiterates Buy Rating
Tweet Send to a Friend
Mizuho Securities analyst, Vamil Divan, reiterated a Buy rating and $104.00 price target on Abbvie (NYSE: ABBV) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
